Dedicated to manufacturing products for the human pharmaceutical market.

In 1997 when LLOYD, Inc., began expansion into human pharmaceuticals, a third marketing division, LLOYD Pharmaceutical, was formed. The first research effort of this new division was directed to levothyroxine sodium tablets USP, building on LLOYD'S twenty year expertise with similar tablets in the veterinary pharmaceutical industry.

The research effort culminated on 24 October 2002 when LLOYD received U.S. Food and Drug Administration (FDA) approval of the New Drug Application, NDA #21-116, for Thyro-Tabs^®, levothyroxine sodium tablets USP.

In 2003 LLOYD, Inc. entered into a business relationship with Forest Laboratories, Inc., to market the human Thyro-Tabs^® products under Forest Pharmaceuticals, Inc.'s brand name Levothroid^®, levothyroxine sodium tablets USP. LLOYD Pharmaceutical formulates and manufactures the tablets, conducts stability testing, and makes all regulatory submissions to FDA concerning the product. Forest Pharmaceuticals packages, labels and distributes the product throughout the United States.